The FDA has approved changes to the prescribing information for finasteride(Proscar) based on results of the landmark Medical Therapy of ProstaticSymptoms (MTOPS) study. Under the new approval, finasteride administeredin combination with doxazosin (Cardura) is indicated to reduce the riskof symptoms of BPH from progressing over time (a confirmed rise of fouror more points in AUA symptom score). MTOPS showed that the two-drug combinationsignificantly reduced the risk of BPH symptoms progressing versus placeboand versus either finasteride or doxazosin alone.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.